Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693613 | 0.82 | KDM4E (0.69) | LMNATP53KDM4EPKMHPGD | |
| SCHEMBL6300238 | 0.82 | KDM4E (0.69) | LMNATP53KDM4EPKMHPGD | |
| SCHEMBL17202513 | 0.81 | LMNA (0.62) | LMNATP53KDM4EPKMHPGD | |
| SCHEMBL23982444 | 0.81 | LMNA (0.62) | LMNATP53KDM4EPKMHPGD | |
| SCHEMBL20419156 | 0.80 | MAPT (0.56) | LMNATP53KDM4EPKMADORA2A | |
| SCHEMBL23982252 | 0.80 | MAPT (0.56) | LMNATP53KDM4EPKMADORA2A | |
| SCHEMBL23982295 | 0.79 | LMNA (0.69) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL23982067 | 0.79 | LMNA (0.69) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL10625750 | 0.79 | LMNA (0.69) | LMNATP53HPGDADORA2AADORA2B | |
| SCHEMBL6687832 | 0.79 | KDM4E (0.71) | LMNATP53KDM4EPKMADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3134411-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | Vitae Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | LMNA 2227/4885TP53 290/4885KDM4E 1413/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | LMNA 2579/4885TP53 301/4885KDM4E 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.